• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Subscribe
  • facebook
  • instagram
  • RSS
  • RSMUS.com

The Real Economy Blog

Search

  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences

Life Sciences

The life sciences sector comprises some of the middle market’s fastest-growing companies. Whether developing life-saving new drugs or robotic components for surgery, this vibrant sector is a hotbed of innovation.

5 things to know this week in life sciences: Week of Jan. 11

Jan. 15, 2021 by Steve Kemler and Adam Lohr

In this week’s roundup, we take a look at life sciences fundraising totals from 2020, which was a record year for the industry in the capital markets. Silicon Valley Bank provides a detailed look at the numbers and provides insights into what to expect this year. Other news this week included Bluebird Bio’s announcement about splitting into two companies, ... READ MORE >

This year may be the busiest ever for health care and life sciences deal volume

Jan. 12, 2021 by Matt Wolf

The annual JP Morgan Healthcare Conference kicks off virtually this week. In years past, the event has heralded announcements of large partnerships, joint ventures and mergers and acquisitions. This year, the health care sector could not even wait until the second full week of January to kick off an acquisition announcement spree. The quick start is an early ... READ MORE >

5 things to know this week in life sciences: Week of Jan. 4

Jan. 7, 2021 by Steve Kemler and Adam Lohr

Each year, pharma companies make updates to their price lists in January. This reliably generates headlines and, occasionally, congressional hearings. In this week’s industry roundup, we take a look at the recent price increases and how they compare to last year’s. We also look at the ongoing battle over 340B program discounts between pharma companies and ... READ MORE >

5 things to know this week in life sciences: Week of Dec. 21

Dec. 23, 2020 by Steve Kemler and Adam Lohr

With approval of Moderna’s COVID-19 vaccine last week for emergency use, many of us are looking forward to getting vaccinated with the hope that it will help us return to a more normal life. While looking forward, this is also a good time to reflect on the decades of work that laid the groundwork for this lightning fast vaccine development effort, as the ... READ MORE >

5 things to know this week in life sciences: Week of Dec. 14

Dec. 16, 2020 by Steve Kemler and Adam Lohr

With the Food and Drug Administration approving the first COVID-19 vaccine for emergency use last week and another approval expected this week, the focus around the vaccine will start to shift toward public health messaging and how to convince tens of millions of people around the country to accept the vaccine and roll up their sleeves for a shot. And ... READ MORE >

5 things to know this week in life sciences: Week of Dec. 7

Dec. 9, 2020 by Steve Kemler and Adam Lohr

COVID-19 vaccine news continues to dominate headlines as candidates from several companies move closer to obtaining emergency use authorization from the Food and Drug Administration. Also on the drug approval front, tech giant Palantir and the FDA entered into a $44 million deal for the agency to use the company’s software in its review process. Plus, we ... READ MORE >

CHART OF THE DAY: Vaccine doses for the global population

Dec. 7, 2020 by Adam Lohr

With the U.S. Food and Drug Administration set to review Pfizer and BioNTech’s COVID-19 vaccine this week for emergency use authorization and Moderna’s vaccine next week, we have passed the “if” phase of questions around the vaccine. Now, the focus turns to the “when and how” of distribution. The United States expects to have enough COVID-19 vaccines ... READ MORE >

Looking ahead: next steps for the economy after Pfizer’s promising vaccine news

Nov. 10, 2020 by Joseph Brusuelas, Adam Lohr and Steve Kemler

Pfizer and German biotech firm BioNTech’s Monday announcement that their COVID-19 vaccine candidate has shown to be more than 90% effective in preliminary results from an ongoing trial is a much needed win in the fight against the pandemic. It carries significant economic implications regarding the potential unlocking of close to $4 trillion in impaired ... READ MORE >

The search for a safe and effective coronavirus vaccine

Oct. 19, 2020 by Adam Lohr and Steve Kemler

Regardless of race, religion or socioeconomic status, one thing most, if not all, Americans can agree on is that we are tired of the pandemic and the economic, health and political fallout we have collectively experienced from it. And while there may be disagreement about the best way to approach the pandemic, it is generally held that a safe, effective ... READ MORE >

More promise, more problems: Cyberattacks threaten life sciences companies researching COVID-19 vaccine

Jul. 22, 2020 by Andrew Weidenhamer, Adam Lohr and Steve Kemler

Picture this scenario: Researchers at a biotech company are working tirelessly on a potential coronavirus vaccine and planning to start a phase three clinical trial soon. This work results in more visibility for the company, and an influx of capital investment. But with that greater visibility and investment comes added risk, especially in the form of ... READ MORE >

Next Page »

Primary Sidebar

Read RSM analysts’ industry coverage of coronavirus.

Categories

  • Economics
  • Technology
  • Consumer Products
  • Industrials
  • Financial Services
  • Real Estate
  • Health Care
  • Life Sciences

Recent articles

  • Biden outlines next round of fiscal aid Jan. 15, 2021
  • 5 things to know this week in life sciences: Week of Jan. 11 Jan. 15, 2021
  • CHART OF THE DAY: OPEC’s response to a drop in demand Jan. 14, 2021

RSMUS.com links

The Real Economy

Middle Market Business Index

MMBI Special Reports

Footer

  • Facebook
  • Instagram
  • RSS

About The Real Economy Blog

The Real Economy Blog from RSM US LLP was developed to provide timely economic insights about the middle market economy. It is offered as a complement to RSM’s macroeconomic thought leadership, including The Real Economy monthly publication and the proprietary RSM US Middle Market Business Index (MMBI).

© 2021 RSMUS.com | Privacy Policy | Cookie Policy

The Real Economy Blog
  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences